Show simple item record

dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorAravantinos, Gerasimosen
dc.contributor.authorKosmidis, Paraskevas A.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorGennatas, Constantinosen
dc.contributor.authorBeer, M.en
dc.contributor.authorMylonakis, N.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorKlouvas, G. D.en
dc.contributor.authorKarpathios, S.en
dc.contributor.authorLinardou, H.en
dc.contributor.authorKonstantaras, C.en
dc.contributor.authorFountzilas, Georgeen
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorAravantinos, Gerasimosen
dc.creatorKosmidis, Paraskevas A.en
dc.creatorPavlidis, Nicholasen
dc.creatorGennatas, Constantinosen
dc.creatorBeer, M.en
dc.creatorMylonakis, N.en
dc.creatorMakrantonakis, P.en
dc.creatorKlouvas, G. D.en
dc.creatorKarpathios, S.en
dc.creatorLinardou, H.en
dc.creatorKonstantaras, C.en
dc.creatorFountzilas, Georgeen
dc.date.accessioned2018-06-22T09:53:14Z
dc.date.available2018-06-22T09:53:14Z
dc.date.issued1996
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41729
dc.description.abstractWe compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CB-EC) in advanced ovarian cancer patients. The treatment was scheduled to be administered every 3 weeks for six courses. Following initial laparotomy and cytoreductive surgery, 130 previously untreated patients entered the study. 73 patients were treated with carboplatin alone while 57 received the combination chemotherapy. In the majority of the patients, the regimens had to be given every 4 weeks due to myelosuppression. Nausea, vomiting and alopecia were more severe in the CB-EC arm. Overall, clinical complete response was observed in 73 (56%) and partial response in 20 (15%) patients. The median time to progression was 16.89 months and median survival was 29.54 months. No significant differences in response rate, time to progression, disease-free survival and overall survival were observed between the two treatment arms. The prognostic role of residual disease after initial surgery, complete remission at second-look laparotomy, tumour stage and performance status was confirmed.en
dc.language.isoengen
dc.sourceEuropean journal of canceren
dc.subjectArticleen
dc.subjectAdulten
dc.subjectCyclophosphamideen
dc.subjectHumanen
dc.subjectAgeden
dc.subjectHumansen
dc.subjectControlled studyen
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectCarboplatinen
dc.subjectDisease progressionen
dc.subjectNeoplasm stagingen
dc.subjectOvarian canceren
dc.subjectOvarian neoplasmsen
dc.subjectPriority journalen
dc.subjectPrognosisen
dc.subjectAlopeciaen
dc.subjectAnemiaen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectBone marrow suppressionen
dc.subjectClinical trialen
dc.subjectControlled clinical trialen
dc.subjectDisease-free survivalen
dc.subjectMulticenter studyen
dc.subjectOndansetronen
dc.subjectProspective studiesen
dc.subjectSurvival analysisen
dc.subjectDexamethasoneen
dc.subjectRandomized controlled trialen
dc.subjectSurvival rateen
dc.subjectEpirubicinen
dc.subjectCarcinomaen
dc.subjectIntravenous drug administrationen
dc.subjectVomitingen
dc.subjectNauseaen
dc.subjectOral drug administrationen
dc.subjectRemission inductionen
dc.subjectOvary carcinomaen
dc.subjectMetoclopramideen
dc.subjectCarboplatin-based chemotherapyen
dc.titleCarboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group studyen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/0959-8049(95)00537-4
dc.description.volume32
dc.description.issue3
dc.description.startingpage421
dc.description.endingpage428
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidAravantinos, Gerasimos [0000-0002-2106-1713]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0002-2106-1713


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record